Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638881 | 0.91 | LMNA (0.53) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| SCHEMBL30754 | 0.91 | LMNA (0.53) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| Glycerin SCHEMBL2582537 | 0.88 | LMNA (0.60) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| SCHEMBL821029 | 0.88 | LMNA (0.50) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| SCHEMBL22279336 | 0.88 | LMNA (0.50) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| SCHEMBL25238278 | 0.88 | LMNA (0.50) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| SCHEMBL10329835 | 0.88 | LMNA (0.50) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| SCHEMBL15894238 | 0.88 | LMNA (0.50) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| Glycerin SCHEMBL314170 | 0.88 | LMNA (0.60) | USP2LMNAALDH1A1KDM4ECYP1A2 | |
| SCHEMBL6249798 | 0.88 | LMNA (0.50) | USP2LMNAALDH1A1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452117-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2329862-B1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | CHARLOTTE MECKLENBURG HOSPITAL (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9023890-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120309825-A1 | Nitrate Esters And Their Use For The Treatment Of Muscle And Muscle Related Diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2529734-A1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | The Charlotte-Mecklenburg Hospital Authority (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8106080-B2 | Mixture of muscle relaxant and nitrogen oxide doner; promote cell muscle proliferation repair; muscle dystrophy therapy | WANG, GUQI (CA) | 2012-01-31 | — | — | US | disclosed |
| EP-2329862-A1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | The Charlotte-Mecklenburg Hospital Authority (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110130455-A1 | Nitrate Esters and Their Use For The Treatment of Muscle and Muscle Related Diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER | 2011-06-02 | — | — | US | disclosed |
| US-20080207713-A1 | Compositions and Methods For Enhancing Nitric Oxide Delivery | ANDERSON, JUDITH E. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2006130982-A1 | COMPOSITIONS AND METHODS FOR ENHANCING NITRIC OXIDE DELIVERY | UNIVERSITY OF MANITOBA (CA) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207713-A1 | Compositions and Methods For Enhancing Nitric Oxide Delivery | TNNC1, NOS1, NOS3 | USP2 2362/4885LMNA 742/4885ALDH1A1 1945/4885 |
| US-20120309825-A1 | Nitrate Esters And Their Use For The Treatment Of Muscle And Muscle Related Diseases | TNNC1, TNNI3, TNNT2 | USP2 713/4885LMNA 568/4885ALDH1A1 1718/4885 |
| US-20110130455-A1 | Nitrate Esters and Their Use For The Treatment of Muscle and Muscle Related Diseases | TNNC1, TNNI3, TNNT2 | USP2 619/4885LMNA 613/4885ALDH1A1 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.